Clinical studies to implement Rheopheresis for age-related macular degeneration guided by evidence-based-medicine
- PMID: 12877897
- DOI: 10.1016/S1473-0502(03)00101-0
Clinical studies to implement Rheopheresis for age-related macular degeneration guided by evidence-based-medicine
Abstract
In the majority of age-related macular degeneration (AMD) patients the therapeutic situation is very unsatisfactory, especially for patients with dry AMD. Rheopheresis is a safe and effective modality of therapeutic apheresis to treat microcirculatory disorders, and represents a novel therapeutic approach for patients with dry AMD and soft drusen. Elimination of a defined spectrum of high molecular weight proteins from human plasma including pathophysiologically relevant risk factors for AMD such as fibrinogen, LDL-cholesterol, alpha 2-macroglobulin, fibronectin, and von-Willebrand factor results in the reduction of blood and plasma viscosity as well as erythrocyte and thrombocyte aggregation. Pulses of lowering blood and plasma viscosity performed as series of Rheopheresis treatments lead to rapid changes of blood flow, subsequently inducing sustained improvement of microcirculation, and recovery of retinal function. Two controlled randomized clinical trials demonstrated safety and efficacy of Rheopheresis for the treatment of AMD patients, especially with the dry form. Recently the interim-analysis of the sham-controlled, double blinded, randomized multicenter MIRA-I trial confirmed these results. The RheoNet-registry and the development and continuous update of therapy guidelines provide an appropriate framework for the quality management of the interdisciplinary cooperation between ophthalmologists with apheresis specialists. A hypothesis based upon current knowledge of pathogenic mechanisms of the development and progression of AMD can be conclusively linked with the putative mechanism of action of Rheopheresis for AMD. A recommendation for high-risk AMD-patients was defined. Based on the positive results of the MIRA-1 interim analysis eight Rheopheresis treatments are currently recommended as the initial treatment series.
Similar articles
-
Rheopheresis for age-related macular degeneration: a novel indication for therapeutic apheresis in ophthalmology.Ther Apher. 2002 Aug;6(4):271-81. doi: 10.1046/j.1526-0968.2002.00418.x. Ther Apher. 2002. PMID: 12164796 Review.
-
Multicenter prospective, randomized, double-masked, placebo-controlled study of Rheopheresis to treat nonexudative age-related macular degeneration: interim analysis.Trans Am Ophthalmol Soc. 2002;100:85-106; discussion 106-7. Trans Am Ophthalmol Soc. 2002. PMID: 12545682 Free PMC article. Clinical Trial.
-
RheoNet registry analysis of rheopheresis for microcirculatory disorders with a focus on age-related macular degeneration.Ther Apher Dial. 2010 Jun;14(3):276-86. doi: 10.1111/j.1744-9987.2010.00807.x. Ther Apher Dial. 2010. PMID: 20609179
-
Clinical outcomes and mechanism of action for rheopheresis treatment of age-related macular degeneration (AMD).J Clin Apher. 2005 Oct;20(3):185-94. doi: 10.1002/jca.20047. J Clin Apher. 2005. PMID: 15892078 Review.
-
Preliminary analysis of the final multicenter investigation of rheopheresis for age related macular degeneration (AMD) trial (MIRA-1) results.Trans Am Ophthalmol Soc. 2006;104:221-31. Trans Am Ophthalmol Soc. 2006. PMID: 17471343 Free PMC article. Clinical Trial.
Cited by
-
Hypoxia-regulated retinal glial cell-specific promoter for potential gene therapy in disease.Invest Ophthalmol Vis Sci. 2011 Nov 1;52(12):8562-70. doi: 10.1167/iovs.10-6835. Invest Ophthalmol Vis Sci. 2011. PMID: 21960554 Free PMC article.
-
Recommendations for Therapeutic Apheresis by the Section "Preparative and Therapeutic Hemapheresis" of the German Society for Transfusion Medicine and Immunohematology.Transfus Med Hemother. 2019 Dec;46(6):394-406. doi: 10.1159/000503937. Epub 2019 Nov 6. Transfus Med Hemother. 2019. PMID: 31933569 Free PMC article. Review.
-
Soluble endoglin as a biomarker of successful rheopheresis treatment in patients with age-related macular degeneration.Sci Rep. 2024 Nov 21;14(1):28902. doi: 10.1038/s41598-024-80375-5. Sci Rep. 2024. PMID: 39572693 Free PMC article.
-
High-sensitivity C-reactive protein, other markers of inflammation, and the incidence of macular degeneration in women.Arch Ophthalmol. 2007 Mar;125(3):300-5. doi: 10.1001/archopht.125.3.300. Arch Ophthalmol. 2007. PMID: 17353399 Free PMC article.
-
[Rheopheresis for age-related macular degeneration].Ophthalmologe. 2009 Feb;106(2):127-32. doi: 10.1007/s00347-008-1768-1. Ophthalmologe. 2009. PMID: 18491113 Review. German.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical